This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowlings, P. A. Articles by Horowitz, M. M. Search for Related Content PubMed PubMed Citation Articles by Rowlings, P. A. Articles by Horowitz, M. M. Social Bookmarking                            What's this?

Increased Incidence of Hodgkin's Disease After Allogeneic Bone Marrow Transplantation

From the International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI; Division of Cancer Epidemiology and Genetics and Division of Cancer Biology and Diagnosis, Laboratory of Pathology, National Cancer Institute, Bethesda, MD; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Department of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia; Department Innere Medizin, Kantonsspital, Basel, Switzerland; and Hôpital Saint Louis, Hématologie-Greffe de Moelle, Paris, France.

Address reprint requests to Rochelle Curtis, MA, Executive Plaza South, Suite 7042, National Cancer Institute, Bethesda, MD 20892; email curtisr{at}epndce.nci.nih.gov

PURPOSE: Immune dysregulation associated with allogeneic bone marrow transplantation (BMT) is linked to an increased risk of posttransplant lymphoproliferative disorders (PTLD); however, reports of Hodgkin's disease (HD) after transplantation are rare.

PATIENTS AND METHODS: We evaluated the risk of HD among 18,531 persons receiving allogeneic BMT between 1964 and 1992 at 235 centers. The number of HD cases was compared with that expected in the general population. Risk factors were identified using Poisson regression and a nested case-control study.

RESULTS: Risk of HD was increased in the postBMT population compared with the general population with an observed-to-expected incidence ratio (O/E) of 6.2 (observed cases, n = 8; 95% confidence interval [CI], 2.7 to 12). A significantly increased risk of HD remained after excluding two human immunodeficiency virus–positive patients (observed cases, n = 6; O/E = 4.7, 95% CI, 1.7 to 10.3). Mixed cellularity subtype predominated (five of eight cases, 63%). Five of six assessable cases contained Epstein-Barr virus (EBV) genome. Posttransplant HD differed from PTLD by later onset (> 2.5 years) and lack of association with established risk factors (such as T-cell depletion and HLA disparity). Patients with HD were more likely than matched controls to have had grade 2 to 4 acute graft-versus-host disease (GVHD), required therapy for chronic GVHD, or both (P = .002), although analysis included small numbers of patients.

CONCLUSION: The increased incidence of HD among BMT recipients adds support to current theories which link overstimulation of cell-mediated immunity and exposure to EBV with various subtypes of HD. The long latency of HD after transplant and lack of association with risk factors for PTLD is noteworthy and should be explored further for possible insights into pathogenesis.

All support information is given in the Appendix.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Hjalgrim, K. Ekstrom-Smedby, K. Rostgaard, R.-M. Amini, D. Molin, S. Hamilton-Dutoit, C. Schollkopf, E. T. Chang, E. Ralfkiaer, H.-O. Adami, et al. Cigarette Smoking and Risk of Hodgkin Lymphoma: A Population-Based Case-Control Study Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1561 - 1566. [Abstract] [Full Text] [PDF]

				R. J. Biggar, E. S. Jaffe, J. J. Goedert, A. Chaturvedi, R. Pfeiffer, E. A. Engels, and for the HIV/AIDS Cancer Match Study Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS Blood, December 1, 2006; 108(12): 3786 - 3791. [Abstract] [Full Text] [PDF]

				B Mester, A Nieters, E Deeg, G Elsner, N Becker, and A Seidler Occupation and malignant lymphoma: a population based case control study in Germany Occup. Environ. Med., January 1, 2006; 63(1): 17 - 26. [Abstract] [Full Text] [PDF]

				R. E. Curtis, C. Metayer, J. D. Rizzo, G. Socie, K. A. Sobocinski, M. E. D. Flowers, W. D. Travis, L. B. Travis, M. M. Horowitz, and H. J. Deeg Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study Blood, May 15, 2005; 105(10): 3802 - 3811. [Abstract] [Full Text] [PDF]

				J. R. Wingard, G. B. Vogelsang, and H. J. Deeg Stem Cell Transplantation: Supportive Care and Long-Term Complications Hematology, January 1, 2002; 2002(1): 422 - 444. [Abstract] [Full Text]

				M. Frisch, R. J. Biggar, E. A. Engels, J. J. Goedert, and for the AIDS-Cancer Match Registry Study Group Association of Cancer With AIDS-Related Immunosuppression in Adults JAMA, April 4, 2001; 285(13): 1736 - 1745. [Abstract] [Full Text] [PDF]